Diagnostik- und Forschungszentrum


Teamleader: Heimo Müller

Main Focus: The focus of our research group lies in the processing and analysis of data generated in the scientific and/or diagnostic process (focus: pathology). On the one hand, tools are developed, which make it possible to process data according to the FAIR principles and, on the other hand, existing algorithms (artificial intelligence) are analyzed and their explainability, including the human-machine interface, is presented and further developed (in cooperation with Andreas Holzinger). In the course of digitization, archive samples from the biobank are also being processed and made available in digital catalogs (in cooperation with Kurt Zatloukal).


HEAP-Human Exposome Assessment Platform

  • The project creates a platform, which is a research resource for efficient analysis of the human exposome. One of the most significant outcomes is the knowledge that researchers consequently have obtained from cohort data, for example, in the context of cervical cancer screening. The platform that is being created here is set up in accordance with the FAIR principles (findable, accessible, interoperable and reusable) and ensures the sustainability of the formats, labeling and access procedures for data.
  • Duration of project: 2020-2024
  • Funded by: European Commission
  • Projectpartner: Karolinska Institutet, Statens Serum Institut (SSI), CSC-TIETEEN TIETOTEKNIIKAN KESKUS OY, LOGICAL CLOCKS AB, Stichting MLC Foundation, Uniwersytet Warszawski, European Science Infrastructure Services EEIG, CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER, BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Oulun Yliopisto, University of Innsbruck


  • To make personal health data (PHD) interoperable, AI-enabled and reusable, the AIDAVA project wants to develop an AI-powered, virtual assistant (tested with hospitals) that maximizes the automation of data maintenance and allows the release of unstructured and structured, heterogeneous data. The virtual assistant includes a curation tool with AI-based personal data that users can access. The focus here is on the breast cancer patient register and longitudinal health records for cardiovascular patients. By increasing automation to improve data quality and deliver high-quality data, AIDAVA will reduce the workload of clinical data stewards, improve the effectiveness of clinical care, and support clinical research.
  • Duration of project: 2022-2026
  • Funded by: European Commission
  • Projectpartner: Universiteit Maastricht, b!loba, European Research and Project Office GmbH, Katholieke Universiteit Leuven, Sirma AI EAD, MIDATA Genossenschaft, The European Institute for Innovation through Health Data, Sihtasutus Pohja-Eesti Regionaalhaigla, Digi.me Limited, Gnome Design SRL, Averbis GmbH, European Cancer Patient Coalition, European Heart Network ASBL

Biobanking and the Cyprus Human Genome Project

  • Genetic testing of diseases and eHealth is a priority of the European project CY-Biobanking and can best be achieved through the creation of a Center of Excellence in Cyprus - as a contemporary biobank research infrastructure and modern research facility to support the project and promote the translat. research focused on genetic diseases. The project upgrades the existing infrastructure and implements high standard procedures and QMS to protect data and material of the highest reliability for later investigation.
  • Duration of project: 2019-2026
  • Funded by: European Commission
  • Project partner: University of Cyprus, BBMRI-ERIC, RTD Talos Limited


  • EMPAIA makes machine decisions transparent, traceable and thus interpretable for a medical expert. Pathologists should be able to understand the context and, if necessary, question a machine decision as to "why". We will develop new methods to measure the quality of explanations and their "causality". Our research results will enable the development of novel "human-AI interfaces" that support the efficient and ethically responsible use of artificial intelligence in medicine (e.g. pathology).
  • Duration of project: 2020-2023
  • Funded by: FFG-The Austrian Research Promotion Agency, ICT of the Future-the funding programme of the Austrian Federal Ministry for Transport, Innovation and Technology (BMVIT)
  • Project Partner: Charité – Universitätsmedizin Berlin, Fraunhofer-Institut für Digitale Medizin MEVIS, DAI-Labor der technischen Universität Berlin, QuIP GmbH, vitagroup AG, Berufsband Deutscher Pathologen e.V., MVZ für Histologie, Zythologie und Molekulare Diagnostik Trier, Biotronik SE &Co.KG, Universitätsklinikum Dresden, Johner Institut, Dierks & Company


  • EOSC-Life brings together European biological and medical research infrastructures to create an open space for collaboration for digital biology. By publishing data and tools on a pan-European cloud, EOSC-Life aims to bring the capabilities of large scientific projects to a wider research community. The goal of the EOSC-Life project is to ensure that life scientists can find, access and integrate life science data for analysis and reuse in academic and industrial research.
  • Duration of project: 2019-2023
  • Funded by: European Commission
  • Project partner: 45 pp a.o. European Molecular Biology Laboratory, BBMRI-ERIC, ECRIN, EATRIS ERIC, INSTRUCT Academic Services Ltd., EMBRC-ERIC, Fraunhofer, CSC, KNAW etc.

BioMedAI Twinning

  • The increasing demand for sophisticated clinical diagnostics makes the current diagnostic capacities insufficient. Artificial Intelligence (AI) and machine learning seem to be very promising approaches to automate diagnostic systems. However, most academic AI systems are opaque black boxes that cannot be understood, tested, and certified without competent knowledge. This motivates Masaryk University and Masaryk Institute of Oncology to collaborate with two advanced partners, the Medical University of Graz and the Technical University of Berlin, and to build a BioMedAI infrastructure that enables close collaboration between computer scientists and clinical experts, reliable AI - to develop explainable solutions. The main part of the BioMedAI project focuses on the training of computer science researchers at the MU and clinical experts at the MMCI in the development of explainable AI methods, validated on medical data basis and in a clinical setting.
  • Duration of project: 2022-2025
  • Funded by: European Commission
  • Projectpartner: Masarykova Univerzita, Technische Universität Berlin, Masarykuv Onkologicky Ustav


  • With colorectal cancer (CRC) accounting for 12.4% of all cancer-related deaths and only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, inexpensive screening tests based on novel ones technologies and increased awareness of the disease and its detection. In addition, personalized approaches to screening are needed to account for genetic and other socioeconomic variables and environmental stressors. ONCOSCREEN responds to these challenges by developing a population-level risk-based stratification methodology for CRC to account for genetic prevalence, socioeconomic status, and other factors. The project is supported by a multidisciplinary consortium of 38 partners, including technical solution providers, hospitals, health ministries as policy makers, legal and ethical experts, insurance companies, and the active involvement of end users/citizens through targeted workshops at all stages of implementation.
  • Duration of project: 2023-2026
  • Funded by: European Commission
  • Projectpartner: EXUS Software Monoprosopi Etairia Periorismenis Evthinis, Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Institute Of Communication And Computer Systems, Firalis, Universitätsklinikum Schleswig-Holstein, Lietuvos Sveikatos Mokslu Universitetas, Technion – Israel Institute Of Technology, Time.Lex, Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, CCASSURED, Universidad De La Rioja, Carr Communications Limited, Ministry Of Health- Greece, Medizinische Universität Innsbruck, Gercor a.o.

Diagnostic and Research Institute of Pathology

Heimo Müller  
T: +43 316 385 71764